oxprenolol has been researched along with sq-11725 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (33.33) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Akamatsu, M | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Allavena, A; Brambilla, G; Gazzaniga, GM; Martelli, A; Mazzei, M; Robbiano, L | 1 |
| Ansuini, R; Belogi, M; Gaggi, S; Pupita, F; Pupita, G | 1 |
| Fishbein, L; Jackson, CD | 1 |
| Alexopoulos, D; Cobbe, SM; Manley, BS; Robinson, GJ | 1 |
| al-Gohary, O; Lyal, J; Murray, JB | 1 |
| Jones, GR; Mir, MA | 1 |
| Chung, DC; Laschuk, MJ | 1 |
| Freis, ED | 1 |
| Abed, J; Donaldson, R; Nashat, F; Taggart, P | 1 |
| Buszewski, B; Krzemiński, TF; Tegowska, E; Welerowicz, T | 1 |
2 review(s) available for oxprenolol and sq-11725
| Article | Year |
|---|---|
A toxicological review of beta-adrenergic blockers.
Topics: Acebutolol; Adrenergic beta-Antagonists; Alprenolol; Animals; Atenolol; Cocarcinogenesis; Ethanolamines; Female; Kinetics; Labetalol; Lethal Dose 50; Male; Metoprolol; Mice; Mutagens; Nadolol; Neoplasms, Experimental; Oxprenolol; Pindolol; Practolol; Propanolamines; Propranolol; Rats; Sotalol; Timolol | 1986 |
The new beta-adrenergic antagonists.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Labetalol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propanolamines; Timolol | 1984 |
3 trial(s) available for oxprenolol and sq-11725
| Article | Year |
|---|---|
Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Female; Heart Diseases; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nadolol; Oxprenolol; Propanolamines; Risk | 1985 |
Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Middle Aged; Nadolol; Nitroglycerin; Oxprenolol; Physical Exertion; Propanolamines; Propranolol | 1981 |
Veterans Administration cooperative study on nadolol as monotherapy and in combination with a diuretic.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Bendroflumethiazide; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Therapy, Combination; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nadolol; Oxprenolol; Propanolamines; Propranolol; Random Allocation; Renin; United States; United States Department of Veterans Affairs | 1984 |
19 other study(ies) available for oxprenolol and sq-11725
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Cell Survival; DNA; DNA Damage; DNA Repair; Humans; Liver; Male; Metoprolol; Nadolol; Nitrosamines; Nitrosation; Oxprenolol; Propranolol; Rats; Rats, Inbred Strains; Sodium Nitrite; Sotalol | 1991 |
Subsidiary class III effects of beta blockers? A comparison of atenolol, metoprolol, nadolol, oxprenolol and sotalol.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Atenolol; Dose-Response Relationship, Drug; Isomerism; Metoprolol; Muscle Contraction; Nadolol; Oxprenolol; Papillary Muscles; Rabbits; Refractory Period, Electrophysiological; Sotalol | 1986 |
Adsorption of antihypertensives by suspensoids. Part 2. The adsorption of acebutolol, metoprolol, nadolol, oxprenolol, and timolol by attapulgite, charcoal, kaolin and magnesium trisilicate.
Topics: Acebutolol; Adsorption; Antihypertensive Agents; Charcoal; Kaolin; Magnesium; Magnesium Compounds; Magnesium Silicates; Metoprolol; Nadolol; Oxprenolol; Silicic Acid; Silicon; Silicon Compounds; Timolol | 1988 |
Class III action of beta-blocking agents.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Atenolol; Cardiac Pacing, Artificial; Dogs; Electrocardiography; Female; Heart; Heart Ventricles; Male; Nadolol; Oxprenolol; Pindolol; Propanolamines; Propranolol; Sotalol; Timolol | 1984 |
Determination of selected beta-receptor antagonists in biological samples by solid-phase extraction with cholesterolic phase and LC/MS.
Topics: Acebutolol; Animals; Cholesterol; Chromatography, High Pressure Liquid; Humans; Male; Mice; Nadolol; Oxprenolol; Propanolamines; Propranolol; Reproducibility of Results; Silicon Dioxide; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Surface Properties | 2009 |